Skip to main content

Table 3 The clinical trials exploring the efficacy of α-PD-1/PD-L1 plus radiotherapy

From: Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Clinical trial

Phase

α-PD-1/PD-L1

Radiotherapy

Cancer type

Primary outcome measures

NCT02608385

1

Pembrolizumab

SBRT

Solid tumors

Recommended SBRT dose

NCT02621398

1

Pembrolizumab

Concurrent chemoradiation

NSCLC

MTD and DLT

NCT02434081

2

Nivolumab

Concurrent chemoradiation

NSCLC

Safety

NCT02586207

1

Pembrolizumab

Concurrent chemoradiation

HNSCC

Safety

NCT02383212

1

Cemiplimab

Concurrent chemoradiation

Solid tumors

Safety, DLT

NCT02402920

1

Pembrolizumab

Concurrent chemoradiation; Concurrent radiation

SCLC

DLT

NCT02904954

2

Durvalumab

SBRT

NSCLC

Pathological response rate

NCT02125461

3

Durvalumab

Concurrent chemoradiation

NSCLC

PFS, OS

NCT02684253

2

Nivolumab

SBRT

HNSCC

BOR

NCT02952586

3

Avelumab

Concurrent chemoradiation

HNSCC

PFS

  1. Abbreviations: SBRT stereotactic body radiotherapy, NSCLC non-small cell lung cancer, MDT maximum tolerated dose, DLT dose limiting toxicity, PFS progression-free survival, OS overall survival, SCLC small cell lung cancer, HNSCC head and neck squamous cell carcinoma, BOR best overall response